# VitriVax funding rounds and investors

As of 19 Nov 2026, VitriVax has raised $87M across 1 verified round on record, plus 1 round still being checked; latest: $87 million Series C led by F-Prime Capital, New Enterprise Associates and 2 others, announced 18 Nov 2026.

A vaccine development and formulation technology company

Website: https://vitrivaxbio.com  
Headquarters: Boulder, Colorado  
Page: https://fireround.dev/companies/vitrivax

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-18 | Series C | $87 million | F-Prime Capital, New Enterprise Associates, RA Capital Management, Sanofi Ventures | Eli Lilly | [vitrivaxbio.com](https://vitrivaxbio.com/vitrivax-announces-87-million-series-c-financing-to-advance-lyme-disease-vaccine-candidate), [businesswire.com](https://www.businesswire.com/news/home/20261118054800/en/VitriVax-Announces-%2487-Million-Series-C-Financing-to-Advance-Lyme-Disease-Vaccine-Candidate-into-the-Clinic-and-Expand-Pipeline), [axios.com](https://www.axios.com/pro/biotech-deals/2026/11/18/vitrivax-87m-lyme-disease-vaccine) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
